Cancer Pharmacology and Pharmacotherapy Review

Double click on above image to view full picture

Zoom Out
Zoom In
Sample Chapter: Chapter 1
Bestseller

Cancer Pharmacology and Pharmacotherapy Review

SKU# 9781620700761

Study Guide for Oncology Boards and MOC Exams

Author: , Anthony J. Perissinotti PharmD, BCOP, Bernard L. Marini PharmD

Francis P. Worden MD

$55.00
  • Other Vendors:

    Amazon

    Buy eBook:

    Amazon Kindle

    Description

    Cancer Pharmacology and Pharmacotherapy Reviewis the first book devoted entirely to providing the "must-know" facts on each cancer agent, including their pharmacokinetics, FDA-approved indications,toxicity, interactions, and other important information that is commonly found on board examinations and essential for any clinician or practitioner to review. The authors, an oncologist and two pharmacists, have developed a handy question-and-answer format to present the material in digestible bursts.

    As the pharmacology section continues to represent a major portion of the medical oncology exam and a key component on oncology MOC exams, this portable study guide will help prepare anyone looking to fine-tune their knowledge on cancer drugs before the test. Not to mention, with recent advancements in the field of cancer treatment, it has become more cumbersome to recall and maintain essential knowledge of every cancer therapeutic, making this book not only an exam resource but also a handy quick reference for oncologists and pharmacists alike.

    KEY FEATURES

    • Conveniently organized and arranged by drug class and subtypes for easier recall and classification
    • Includes proper dosage adjustments to account for liver and kidney dysfunction
    • Features tables throughout that provide quick reference regarding FDA-approved medications
    • Simplified diagrams and illustrations facilitate the pharmacokinetic processes

    Product Details

    • Publication Date March 14, 2016
    • Page Count 208
    • Product Form Paperback / softback
    • ISBN 13 9781620700761
    • EISBN

    About The Author(s)

    Professor of Medicine, and Director of the Hematology/Oncology Fellowship Program at University of Michigan Medical School in Ann Arbor, Michigan

    Table of Contents

    Contents

    List of Figures

    List of Tables

    Preface

    I. Traditional Chemotherapy

    1. Microtubule Inhibitors

    Taxanes and Related Agents

    Vinca Alkaloids

    2. Alkylating Agents

    Nitrogen Mustards

    Non-Nitrogen Mustards

    Platinums

    Antitumor Antibiotics

    3. Enzyme Inhibitors—Topoisomerase I Inhibitors

    Camptothecans

    4. Enzyme Inhibitors—Topoisomerase II Inhibitors

    Epipodophyllotoxins

    Anthracyclines

    5. Antimetabolites

    Antifolates

    Purine Antagonists

    Purine Analogues

    Pyrimidine Analogues/Fluoropyrimidines

    Pyrimidine Analogues/Deoxycytidine Analogues

    II. Next-Generation Antineoplastics

    6. Monoclonal Antibodies

    7. VEGF Trap

    Ziv-Aflibercept (Zaltrap®)

    8. Tyrosine Kinase Inhibitors

    Angiogenesis Inhibitors and Multi-Kinase Inhibitors

    Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-ABL) Inhibitors

    B-Cell Receptor (BCR) Pathway Inhibitors

    EGFR-Ras-Raf-MEK-ERK (MAPK) Pathway Inhibitors

    Miscellaneous Oral Targeted Therapies

    9. Antiandrogen Therapies

    10. Mammalian Target of Rapamycin (mTOR) Inhibitors

    11. Histone Deacetylase (HDAC) Inhibitors

    12. Hypomethylating Agents

    13. Proteasome Inhibitors

    14. Immunomodulatory Agents

    15. L-Asparaginase Enzymes

    16. Promyelocytic Leukemia Gene Retinoic Acid Receptor-Alpha (PML-RARα) Translocation Inhibitors

    III. Miscellaneous Oncolytics

    17. Sipuleucel-T (Provenge®)

    18. Omacetaxine (Synribo®)

    19. Estramustine (Emcyt®)

    Appendix A: Agents Requiring Renal and/or Hepatic Dose Adjustments

    Appendix B: Extravasation Risk of Chemotherapeutic Agents

    Index